3CAI – 250 mg

Brand:
Cayman
CAS:
28755-03-5
Storage:
-20
UN-No:
Non-Hazardous - /

3CAI is an inhibitor of Akt1 and Akt2 with anticancer activity.{41924} It inhibits Akt1 and Akt2 in a kinase assay in a concentration-dependent manner, but has no effect on MEK1, JNK1, ERK1, or PDZ binding kinase (PBK) when used at a concentration of 1 µM. 3CAI (4 µM) increases apoptosis in HCT116 and HT-29 colon cancer cells and inhibits the growth of HCT116 cells in vitro in a concentration-dependent manner. Oral administration of 3CAI (30 mg/kg) reduces tumor growth in an HCT116 mouse xenograft model. It also decreases status epilepticus-induced vasogenic edema to 0.46-fold of vehicle control levels and reduces increases in endothelial nitric oxide synthase (eNOS) levels in the piriform cortex in rats when administered at a dose of 25 µM.{41925}  

 

SKU: - Category:

Description

An inhibitor of Akt1 and Akt2 with anticancer activity; inhibits Akt1 and Akt2 in a kinase assay, but has no effect on MEK1, JNK1, ERK1, or PBK at 1 µM; increases apoptosis in HCT116 and HT-29 colon cancer cells at 4 µM; inhibits growth of HCT116 cells in vitro; reduces tumor growth in an HCT116 mouse xenograft model at 30 mg/kg; decreases status epilepticus-induced vasogenic edema and reduces increases in eNOS levels in the piriform cortex in rats at 25 µM


Formal name: 2-chloro-1-(1H-indol-3-yl)-ethanone

Synonyms:  3-chloroacetyl Indole

Molecular weight: 193.6

CAS: 28755-03-5

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PKB/Akt||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Neuroscience|Seizure Disorders